SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001178913-12-002173
Filing Date
2012-08-07
Accepted
2012-08-07 11:49:33
Documents
1
Group Members
CLAL INDUSTRIES & INVESTMENTS LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A zk1211814.htm SC 13D/A 159317
  Complete submission text file 0001178913-12-002173.txt   160909
Mailing Address BECK SCIENCE CENTER 8 HARTOM STREET, HAR HOTZVIM JERUSALEM L3 97775
Business Address BECK SCIENCE CENTER 8 HARTOM STREET, HAR HOTZVIM JERUSALEM L3 97775 972-2-548-6555
BIOCANCELL THERAPEUTICS INC. (Subject) CIK: 0001451980 (see all company filings)

IRS No.: 204630076 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-84912 | Film No.: 121012034
SIC: 2834 Pharmaceutical Preparations

Mailing Address 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR TEL AVIV L3 67023
Business Address 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR TEL AVIV L3 67023 972-3-6075794
Clal Biotechnology Industries Ltd. (Filed by) CIK: 0001468950 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13D/A